Complera Lawsuit

Lawsuits recently filed charge Gilead Sciences, the maker of widely-prescribed class of HIV medications that includes Complera, with bringing a defective drug to market, and of unnecessarily exposing the public to a risk of serious side effects when there are a variety of safer, less dangerous HIV drugs available.

Free Confidential Lawsuit Evaluation: If you or a loved one has been harmed by the side effects of Complera or another tenofovir-containing HIV medication, you should contact our law firm immediately. You may be entitled to compensation by filing a suit against Gilead Sciences and our lawyers can help.

Update: Judge Clears Suit Alleging Gilead HIV Medications Defectively Designed

May 11, 2019 – U.S. District Judge Jon S. Tigar has greenlighted a lawsuit filed by a group of patients accusing Gilead Sciences Inc. of negligence, products liability, and a host of other allegations surrounding its tenofovir disoproxil fumarate- containing HIV drugs, but agreed to narrow the scope of the case by tossing allegations that Gilead hid knowledge that the medicines are “unreasonably and unnecessarily unsafe.” Tigar cleared various other claims made in the suit, including design defect, negligence and product liability claims.

What is Complera?

Complera combines the drugs Truvada (generic: emtricitabine and tenofovir disoproxil fumarate) and Edurant (rilpivirine) for a complete once-a-day HIV-1 treatment. The drug is made by Gilead Sciences, and was approved by the U.S. Food & Drug Administration (FDA) in August 2011.

Complera Dosage

The recommended dosage of COMPLERA in adults and children at least 35 kg (77 lbs.) is one tablet taken orally once daily with food, according to Gilead Sciences.

What’s the Problem?

One recently-filed lawsuit claims that HIV patients suffered from up to a decade of “additional accumulated kidney and bone toxicity” from tenofovir disoproxil fumarate, an ingredient in Complera and its other HIV drugs, while the manufacturer withheld an equally effective yet safer product from the public. Lawyers claim that Gilead knew that their HIV drugs had to be given in high doses to be effective, which meant they could damage the kidneys and bones, yet the company failed to adequately warn patients or doctors about those side effects on the medicine’s label. Gilead is now urging doctors to switch their patients to the new drugs to reduce possible harm to their kidneys and bones.